Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine

INTRODUCTION: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM) despite advances in chelation therapy. The aim of this study was to compare the effectiveness and safety of deferasirox (DFX) and deferoxamine (DFO) as iron-chelating agents in patients with transfu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Mohamed Abdel Malik, Tolba, Omar Atef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Electronic physician 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930264/
https://www.ncbi.nlm.nih.gov/pubmed/27382454
http://dx.doi.org/10.19082/2425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930264/
https://www.ncbi.nlm.nih.gov/pubmed/27382454
http://dx.doi.org/10.19082/2425

Ejemplares similares